Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CMIC Co, Ltd. Japan | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this surveillance is to confirm the safety and efficacy of TBE under actual use in the Zone 0/1 lesion on post-marketing usage conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aneurysm cohort | Thoracic Aortic Aneurysm: 50 patients (including at least 5 surgically repaired patients who have the proximal landing zone that is a surgical graft) Before 5 surgically repaired patients are enrolled if the other 45 patients are confirmed to be enrolled, enrollment of the other patients will be considered complete at that point, and only surgically repaired patients will continue to be enrolled. |
| |
| Dissection and Traumatic Transection cohort |
If, during the enrollment period for the dissection and traumatic transection cohort, an attempt is made to place TBE in patients with complicated acute Stanford type B aortic dissection or in patients with traumatic thoracic aortic transection, those patients will also be enrolled in the dissection and traumatic transection cohort. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gore® TAG® Thoracic Aortic Branch Stent Graft System | Device | Patients who attempted implant of TBE in Zone 0/1 during the enrollment period for each indication (including patients in whom TBE is not placed in Zone 0/1 area). |
| Measure | Description | Time Frame |
|---|---|---|
| Device Technical Success at the Initial Endovascular Procedure | All of the following must be met.
| TBE Initial Implant Procedure |
| Lesion-related Mortality and All-cause Death | Lesion-related Mortality that meet any of the following criteria:
| 60 Months |
| Aortic Rupture of the Treatment Lesion | Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or CT / CTA scan. | 60 Months |
| Disabling Stroke | Stroke is the acute onset of symptoms consistent with focal or multifocal central nervous system (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: Persists for > 24 hours or until death | 60 Months |
| Serious Paraplegia | Paraplegia secondary to spinal cord ischemia reported as a serious adverse event from sites. | 60 Months |
Not provided
Not provided
Inclusion Criteria:
Those who are suitable for use of TBE according to the Japan package insert. [Reference: Purpose of Use or Effects of TBE at the time of launch] The GORE® TAG® Thoracic Branch Endoprosthesis is intended for use in patients with the following diseases of the aortic arch and descending thoracic aortic lesions who fulfill anatomical requirements for treatment of such diseases while preserving blood flow to a single aortic arch target branch vessel.
The GORE® TAG® Thoracic Branch Endoprosthesis may be used in combination with designated stent grafts with validated efficacy and safety.
Exclusion Criteria:
N/A
Not provided
Not provided
Not provided
Not provided
Patients who attempted implant of TBE in Zone 0/1 during the enrollment period for each indication (including patients in whom TBE is not placed in Zone 0/1 area).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Manami Kaneko | Contact | +81-70-1433-0565 | mkaneko@wlgore.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001014 | Aortic Aneurysm |
| D000784 | Aortic Dissection |
| D014947 | Wounds and Injuries |
| ID | Term |
|---|---|
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001018 | Aortic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Serious Paraparesis |
Paraparesis secondary to spinal cord ischemia reported as a serious adverse event from sites. |
| 60 Months |
| Renal Failure Requiring Dialysis | Renal failure reported as a serious adverse event by sites and confirmed to require dialysis. | 60 Months |
| Additional Unanticipated Post-procedural Reintervention | Additional unanticipated surgical procedure or endovascular procedure related to TBE, TBE implant procedure, or revascularization procedure for TBE implant after the revascularization procedure or TBE implant procedure. Anticipated or unanticipated status will be determined at the discretion of the investigator. Surgical procedures include conversion to thoracotomy. Endovascular procedures include stent graft implants for endoleaks, aortic enlargement and loss of patency, and procedures on the branch to improve or restore patency. Events will not include access site(s) complications, interventions to address issues related to non-treated area of the index lesion, such as bare stent implant to address bowel ischemia associated with aortic dissection. | 60 Months |
| Serious Device-related Ischemia | Ischemia reported by sites as a serious adverse event determined to be related to the device. | 60 Months |
| Distal Device-related Thromboembolic Serious Adverse Event Requiring Intervention or Surgery | Device-related ischemic adverse events reported by sites as serious adverse events that required bypass surgery, surgical procedures, or amputation, or that resulted in death. | 60 Months |
| Serious New Dissection | New events of aortic dissection reported as serious adverse events by sites. | 60 Months |
| Serious Myocardial Infarction | Myocardial infarction reported as a serious adverse event by the sites. | 60 Months |
| Serious Laryngeal or Phrenic Nerve Injury | Nerve damage events reported by the sites as serious adverse events that required retreatment. | 60 Months |
| Serious Heart Failure/Hypotension | Heart failure or hypotension reported as serious adverse events by the sites. | 60 Months |
| Aortic Enlargement in the Region Encompassed by the Initial Lesion | An increase of 5 mm or more in arterial diameter at the treated area compared to images taken at the first follow-up after the TBE implant procedure. | 60 Months |
| Endoleak | Serious adverse events reported or confirmed by imaging by the sites. The definitions of each type of endoleaks are as follows:
| 60 Months |
| Loss of Device Integrity | Defined as any of the following:
| 60 Months |
| Loss of Aortic or Aortic Branch Patency | No flow or contrast detected through the implanted aortic or side branch devices or distal CTAG devices after the TBE implant procedure. | 60 Months |
| Migration | Longitudinal movement of all or part of the device for a distance ≥10 mm, as confirmed by imaging, relative to anatomical landmarks and device positioning at the first post-operative imaging. | 60 Months |
| False Lumen Perfusion through the Primary Entry Tear (Dissection Patients only) | Confirm the presence or absence of blood flow from a proximal aortic source through the primary entry tear into the aortic false lumen, based on imaging. | 60 Months |
| Extension of a Dissection (Proximally or Distally) (Dissection Patients only) | Among the aortic dissections reported by sites as serious adverse events, those in which proximal or distal progression of the lesion from the TBE implant procedure was confirmed on imaging. | 60 Months |
| False Lumen Status in Treated and Untreated Segments (Dissection Patients only) | The thrombosis state of the false lumen at the treated and untreated segments at the TBE implant procedure is confirmed using the following three stages.
| 60 Months |
| D000094665 |
| Dissection, Blood Vessel |
| D000094683 | Acute Aortic Syndrome |